Wikipedia -WSS

Wikipedia

author：hotspot 2025-09-29 16:45:45 - browse：4842

Stock illustration of computer and medication — Adobe

Digital therapeutics company Click Therapeutics announced Wednesday it will acquire the assets of Better Therapeutics, developer of a software-based treatment for diabetes. Click, which did not disclose how much it is paying for the assets, hopes to adapt Better’s tech for use alongside GLP-1 medications.

Better Therapeutics announced in March that it was delisting from the Nasdaq stock exchange and shutting down operations as it sought strategic alternatives. The company had been, since last year, searching for ways to stay afloat as its cash reserves dwindled.

Last, year, Better received Food and Drug Administration clearance for AspyreRx, a prescription app that delivers cognitive behavioral therapy and had been shown to reduce A1c levels in people with type 2 diabetes. Still, the company has been unable to ramp up significant commercial traction. Better also had a pipeline of other products targeting cardiometabolic conditions, and had made early claims about the benefits of AspyreRx in people taking GLP-1s for diabetes management.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： Case highlights the risks of experimental stem cell therapy

hotspot

WSS

How to make AI work for medicine

How Long Island became the ‘eugenics capital of the world’

As pharma fights Medicare drug negotiation, hospitals, docs silent

AstraZeneca bets AAV gene therapy will still deliver the goods

Neuroscience startup Neumora files for IPO

How a symptom of dementia informs our understanding of creativity

focus

Wikipedia

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

focus

Peter Hotez and the public health issue of online harassment

What AAP's gender

Heart attack and stroke risk calculators need revising

Medicare explains how it will choose drugs for negotiation

State Dept. review finds Biden bears some blame for Afghanistan failures

Arc Institute generative AI designs new CRISPR systems

FDA approval of Sarepta Duchenne genetic therapy gives me hope

FDA panel gives mixed vote on blood pressure devices

In Memoriam: Notable people who died in 2023

NYU Langone launches private ChatGPT for its health care data

hotspot

NVIDIA and Google execs on the future of AI and drug discovery

Arc Institute generative AI designs new CRISPR systems

AstraZeneca bets AAV gene therapy will still deliver the goods

Readout Newsletter: Nvidia, Biogen, Ionis, AstraZeneca, ChatGPT

Complete sequence of Y chromosome published for first time

FDA panel gives mixed vote on blood pressure devices

hotspot

Wikipedia

focus

hotspot